The metabolic fate of the anti-parkinsonian drug budipine in rats.
The metabolic fate of the anti-Parkinsonian drug budipine was studied in rats after oral administration. The presence of an aromatic hydroxylation product, metabolite M1, and its O-sulphate conjugate was confirmed. Three new minor metabolites, budipine N-oxide, metabolite M1 N-oxide and a secondary metabolite derived from M1 via hydroxylation of a methyl of the tert-butyl group, were isolated and identified in rat urine. The presence of a metabolite M1-glucuronic acid conjugate, was also established through different enzymatic treatments of the rat urine.
Istituto di Chimica Farmaceutica Applicata, Università di Torino, Italy.
O
O
Caputo
G
G
Grosa
M
M
Ceruti
F
F
Rocco
G
G
Biglino
D000818:Animals; D000978:Antiparkinson Agents / Q000378:metabolism* / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D005965:Glucuronates / Q000378:metabolism / Q000652:urine; D006900:Hydroxylation; D008297:Male; D010880:Piperidines / Q000378:metabolism* / Q000652:urine; D051381:Rats; D011919:Rats, Inbred Strains; D013056:Spectrophotometry, Ultraviolet
D000978:Antiparkinson Agents; D005965:Glucuronates; D010880:Piperidines; C026710:budipine